


## SM1-71

<b>Cat. No.:</b>	HY-136848
<b>CAS No.:</b>	2088179-99-9
<b>Molecular Formula:</b>	C <sub>24</sub> H <sub>26</sub> ClN <sub>7</sub> O
<b>Molecular Weight:</b>	463.96
<b>Target:</b>	MAP3K; Src; FGFR; Ribosomal S6 Kinase (RSK); LIM Kinase (LIMK)
<b>Pathway:</b>	MAPK/ERK Pathway; Protein Tyrosine Kinase/RTK; Cell Cycle/DNA Damage
<b>Storage:</b>	Please store the product under the recommended conditions in the Certificate of Analysis.



### BIOLOGICAL ACTIVITY

<b>Description</b>	SM1-71 (compound 5) is a potent TAK1 inhibitor, with a K <sub>i</sub> of 160 nM, it also can covalently inhibit MKNK2, MAP2K1/2/3/4/6/7, GAK, AAK1, BMP2K, MAP3K7, MAPKAPK5, GSK3A/B, MAPK1/3, SRC, YES1, FGFR1, ZAK (MLTK), MAP3K1, LIMK1 and RSK2. SM1-71 can inhibit proliferation of multiple cancer cell lines <sup>[1][2][3]</sup> .								
<b>IC<sub>50</sub> &amp; Target</b>	IC <sub>50</sub> : 0.8 nM (GAK), 0.8 nM (YES1), 2 nM (SRC), 4.4 nM (AAK1), 5.4 nM (LIMK1), 7.1 nM (BMP2K), 9.3 nM (MAP2K2), 10.4 nM (MAP2K1), 28.7 nM (MAP3K1), 48.3 nM (MAPK1), 107 nM (MAPK3) <sup>[1]</sup>								
<b>In Vitro</b>	<p>SM1-71 (0.001-100 μM; 72 h) potently inhibits the proliferation of H23 and Calu-6 non-small cell lung cancer cell lines with a concentration-dependent manner<sup>[1]</sup>.</p> <p>SM1-71 (72 h) induces potent cytotoxicity with nanomolar values for GR<sub>50</sub> and negative GR<sub>max</sub> values in eight of 11 cancer cell lines<sup>[2]</sup>.</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <p>Cell Viability Assay<sup>[1]</sup></p> <table border="1"> <tr> <td>Cell Line:</td> <td>H23-KRAS<sup>G12C</sup> and Calu-6-KRAS<sup>Q61K</sup> cells</td> </tr> <tr> <td>Concentration:</td> <td>0.001, 0.01, 0.1, 1, 10, 100 μM</td> </tr> <tr> <td>Incubation Time:</td> <td>72 hours</td> </tr> <tr> <td>Result:</td> <td>Inhibited proliferation of H23-KRAS<sup>G12C</sup> and Calu-6-KRAS<sup>Q61K</sup> cells with IC<sub>50</sub>s of 0.4 and 0.3 μM, respectively.</td> </tr> </table>	Cell Line:	H23-KRAS <sup>G12C</sup> and Calu-6-KRAS <sup>Q61K</sup> cells	Concentration:	0.001, 0.01, 0.1, 1, 10, 100 μM	Incubation Time:	72 hours	Result:	Inhibited proliferation of H23-KRAS <sup>G12C</sup> and Calu-6-KRAS <sup>Q61K</sup> cells with IC <sub>50</sub> s of 0.4 and 0.3 μM, respectively.
Cell Line:	H23-KRAS <sup>G12C</sup> and Calu-6-KRAS <sup>Q61K</sup> cells								
Concentration:	0.001, 0.01, 0.1, 1, 10, 100 μM								
Incubation Time:	72 hours								
Result:	Inhibited proliferation of H23-KRAS <sup>G12C</sup> and Calu-6-KRAS <sup>Q61K</sup> cells with IC <sub>50</sub> s of 0.4 and 0.3 μM, respectively.								

### REFERENCES

- [1]. Rao S, et, al. Leveraging Compound Promiscuity to Identify Targetable Cysteines within the Kinome. *Cell Chem Biol*. 2019 Jun 20; 26(6): 818-829.e9.
- [2]. Rao S, et, al. A multitargeted probe-based strategy to identify signaling vulnerabilities in cancers. *J Biol Chem*. 2019 May 24;294(21):8664-8673.
- [3]. Tan L, et, al. Structure-guided development of covalent TAK1 inhibitors. *Bioorg Med Chem*. 2017 Feb 1; 25(3): 838-846.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA